Biomarker-Guided cocktail aims to slow kidney failure
NCT ID NCT07239570
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether using specific biomarkers to choose and combine three kidney-protecting drugs (dapagliflozin, semaglutide, and finerenone) can slow kidney function decline better than standard care. About 125 adults with chronic kidney disease and albuminuria will be randomly assigned to either the biomarker-guided approach or usual treatment. The goal is to see if personalized drug sequencing preserves kidney function over two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dapagliflozin, Semaglutide, Finerenone
What this could lead to
If successful, this could show that matching drugs to individual biomarkers slows kidney function decline better than standard care, improving long-term outcomes for millions with chronic kidney disease.
What could go wrong
This is a phase 4 trial with 125 participants, so results may not apply to all patients. The benefit over standard care may be small, and side effects from combining these drugs are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE (CKD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Clinico de Valencia
NOT_YET_RECRUITINGValencia, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lund University
NOT_YET_RECRUITINGMalmö, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Steno Diabetes Center Copenhagen
RECRUITINGHerlev, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Medical Center Hamburg-Eppendorf
NOT_YET_RECRUITINGHamburg, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••